Gantenerumab May Delay Alzheimer Disease Symptoms in High-Risk Adults: Daily Dose
Your daily dose of the clinical news you may have missed.
Failure to Follow-Up After Colorectal Cancer Screening Translates into Preventable Deaths: Rachel Issaka, MD, MAS
ACP 2025: Issaka, from the Fred Hutchinson Cancer Center, told internists that three-quarters of CRC deaths can be attributed to 3 types of screening failure.
Aprocitentan Reduces BP in Black Adults with Resistant Hypertension and Lowers Proteinuria
Aprocitentan, when added to background therapy of at least 3 antihypertensive agents, led to clinically meaningful and sustained BP reduction in this preplanned subanalysis.
RSV Vaccine Uptake Low Among Eligible Populations, Large-Scale Analysis Finds
AAAAI 2025: RSV vaccine and immunoprophylaxis uptake remained low in 2024 across infants, pregnant individuals, and older adults.
Second Measles-Related Death in a Child Reported in Texas as US Cases Surpass 600
As the US measles outbreak tops 600 cases, Texas reported a second child's death in a young girl who was unvaccinated and had no underlying health conditions.
Closing the Gap in Lung Cancer Screening: Overcoming Barriers, Improving Early Detection
ACP 2025: Kim Sandler, MD, outlines key strategies to boost lung cancer screening uptake in primary care.
Primary Care Primer for Headache Management, with Morris Levin, MD
ACP 2025. The director of the UCSF Headache Center built an evidence-based framework for diagnosing and treating headache disorders seen in primary care.
Antibiotic Overuse for Asymptomatic UTIs: Daily Dose
Navigating GLP-1 Medication Access: Coverage Challenges, Emerging Cash-Pay Options
ACP 2025: Laura Davisson, MD, outlines how PCPs can navigate GLP-1 medication coverage issues and why to consider recent cash-pay options.
Eisai Presents Real-World Lecanemab Data at AD/PD 2025 Confirming Phase 3 Clinical Trial Findings
In addition to support for phase 3 CLARITY AD findings, new evidence was presented supporting lecanemab safety and efficacy in ApoE ε4 carriers and non-carriers.
Bringing Mental Health into Primary Care: A Conversation with Matthew Press, MD
ACP 2025: Dr Press explains how primary care clinicians can implement the collaborative care model to integrate mental health services, improve outcomes, and navigate reimbursement.
Alphyn Biologics Initiates Phase 2b Trial of Botanical Drug for Atopic Dermatitis
The investigational botanical zabalafin hydrogel has shown antipruritic, antibacterial, and anti-inflammatory properties, addressing the multifactorial nature of AD.
ASCVD in Women is Different: A Review of Pathophysiology, Risk Factors, Presentation
ACP 2025. Karol E Watson, MD, PhD, highlighted how traditional approaches to CV care have poorly addressed the unique presentations, risk factors, and pathophysiology of heart disease in women.
Guselkumab (Tremfya) Gains FDA Approval for Crohn Disease: Daily Dose
CVD Prevention in Older Adults: Crucial and Also Controversial
ACP 2025. Harvard gerontologist and preventive cardiologist Ariela Orkaby, MD, MPH, highlighted the many nuances required in the cardiovascular care of the aging population.
Shared Decision-Making in Lung Cancer Screening: A Collaborative Approach
ACP 2025: Kim Sandler, MD, explains how primary care physicians can use shared decision-making to guide patients through lung cancer screening, emphasizing risk, benefit, follow-up, and smoking cessation.
Racial and Ethnic Disparities in Pediatric Atopic Dermatitis Prevalence and Care are Persistent and Significant: New Scoping Review
Black children were 2.4 to 4.1 times more likely to experience early-onset and persistent disease than White peers and much more likely to require urgent care for their AD.
Benefits of Lung Cancer Screening: A Conversation with Kim Sandler, MD
ACP 2025: Kim Sandler, MD, sat down with Patient Care to discuss the benefits of lung cancer screening, citing a 20% reduction in lung cancer mortality with annual screenings.
Trontinemab: Roche Announces Phase 3 Development Program for the mAb in Adults with Early Alzheimer Disease
Using the proprietary Roche Brainshuttle technology, trontinemab leads to deep, rapid amyloid plaque reduction with a favorable safety profile.
FDA Approves Gepotidacin for Treatment of Uncomplicated UTIs: Daily Dose
